Clinical Trials at Risk
Suddenly the risk-reward balance has shifted dramatically. Anyone with basic cold symptoms is being advised to stay home. And many people can no longer travel with COVID-19 in their community.
What if you can no longer visit your sites? Are you ready to use the tools at your disposal as contingency or risk-mitigation strategies to keep your studies going and ensure your patients can access their study medication and remain safely monitored?
During this virtual discussion forum we’re putting our minds together to combat the impact of the Coronavirus outbreak on clinical trials, and be better prepared in the future.
The MINDS-ON think tank
- Craig Lipset, Former Head of Clinical innovation at Pfizer
- Derk Arts, Founder & CEO Castor EDC
- Nancy Meyerson-Hess, Chief Compliance & Regulatory Officer at eMQT, Expert Partner at admedicum
- Andy Lawton, Consultant at Risk Based Approach Ltd
- Dr Johann Proeve, CSO Cyntegrity
Some of the dilemma’s to address
What do we need to do in order to guarantee safety and data integrity?
What are the various COVID-19 scenarios that impact clinical trial operations?
Coronavirus will be on the minds of the patients you are engaging as participants in clinical trials. How are you preparing for patients concerns?
What do the sites have to say? They are on the front line with patient interactions and engagement.
Are clinical trial planners today considering technologies (remote monitoring, telemedicine) as contingencies to ensure their patients can continue safely on investigational medicines?
In what way will COVID-19 reshape how clinical trials will be done?
Are we going to see a larger shift to decentralized trials, and at a faster rate than sponsors have planned?